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The ability of the Cystic Fibrosis pathogen, Burkholderia cepacia complex (Bcc)
to form bioﬁlms plays a key role in resistance to host defence mechanisms and
antibiotic therapy. The objectives of this study were to determine the antibiotic
susceptibility of Bcc bioﬁlms and the effects of efﬂux pump inhibitors (EPI)
in combination with antibiotics, to enhance susceptibility. Confocal analysis of
antibiotic treatment of B. multivorans and B. dolosa bioﬁlms with tobramycin
resulted in decreased bioﬁlm thickness. Ciproﬂoxacin had no effect on B. dolosa
bioﬁlm thickness. Ceftazidime treatment did not decrease Bcc bioﬁlm biomass,
but the cells within the bioﬁlms formed “spindle” like structures. Interestingly,
B. cenocepacia bioﬁlms appeared to form thicker and more structured bioﬁlms in the
presence of the antibiotics. The effect of EPIs on minimum inhibitory concentrations
(MIC) of Bcc strains against a panel of antibiotics was investigated and found a
two fold decrease in MIC values in the presence of EPIs. We also investigated the
effects of the EPIs on the formation and metabolic activity Bcc bioﬁlms, where 1-(1-
naphthylmethyl)-piperazine (NMP) was found to be most effective at decreasing the
formation of Bcc bioﬁlms. Additionally, two B. dolosa 24 hour bioﬁlms were found
to be metabolically inactive when treated with NMP at 100mg/ml and at 50mg/ml
in combination with 100mg/ml Thiorizadine. This work demonstrates that antibiotic
susceptibility of Bcc is affected by bioﬁlm maturity, strain and antibiotic type thus
highlighting the need for a greater understanding of Bcc bioﬁlm antibiotic resistance
mechanisms.
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Intravenous colistin has been associated to dose-dependent nephrotoxicity and neu-
rotoxicity. We conducted a retrospective analysis of the electronic records of patients
hospitalized between April 2009 and March 2010 who received colistimethate
sodium (colistin) i.v. We collected data on their weight, drug dosage, ADRs reported
during the treatment, and associated treatments. Data of 308 patients were reviewed
for a total of 445 hospitalizations. We identiﬁed 30 patients treated on 35 episodes.
Mean dose was 124,000U/kg/die. Nine patients experienced an ADR. They had
received 121.000 U/kg/die (range 44,500–199,000U/kg/die). This dose was not
statistically different from the dose received by patients (26) who did not experience
ADRs (121,800U/kg/die, range 49,800–169,000U/kg/die). The main reactions were
neurologic (such as perioral paresthesias, asthenia and weakness) and nephrotoxic
(ipercreatinemia): all were reversible. We did not ﬁnd an increased rate of renal
effects when aminoglycoside were associated.
Conclusions: IV colistin is still a valuable drug in the treatment of pulmonary ex-
acerbations in CF. However ADRs are frequent and not necessarily dose-dependent.
At the time we support the view that treatment should start with a low dosage with
stepwise increases but large, prospective trials are warranted to study other factor
risks in cystic ﬁbrosis patients.
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During chronic respiratory infections, patients with cystic ﬁbrosis (CF) suffer more
or less frequently from acute exacerbations (AEs) which are characterized by several
clinical symptoms including increased cough and sputum production. It has been
proposed that the symptoms of an AE are largely due to the incidental release
of planktonic bacterial organisms from bioﬁlms which are present in airways of
virtually all infected CF patients. We assessed this hypothesis in an open prospective
clinical study, in which we determined P. aeruginosa DNA by nested PCR and qPCR
in blood specimens of 43 CF patients, chronically infected with P. aeruginosa,
obtained during AE and 10 to 14 days after antibiotic treatment, when the patient
was clinically stable. The majority of CF patients (72%) had a positive blood
PCR for P. aeruginosa. Positive P. aeruginosa PCRs were observed in 68% of the
patients during AEs, and in 32% of clinically stable patients. qPCR revealed the
presence of ~104 bacterial cells per ml of blood during AE which was signiﬁcantly
greater than levels in clinically stable CF patients. Nested PCR for Escherichia
coli and Prevotella intermedia were negative in all cases. We conclude that AEs
are correlated with a release of P. aeruginosa from infected airways into the blood
stream. These results provide a novel rational for antibiotic therapy during AEs in
CF.
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I-neb Insight Online is a telemedicine-based patient management system for use
with the I-neb AAD System to monitor patient adherence to treatment, compliance
with correct use and cleaning of the I-neb AAD System device. The I-neb AAD
System is equipped with a patient logging system (PLS) that records device use.
True Adherence (TA) is calculated using % adherence to prescribed regimen x %
compliance with correct use / 100 and is an important indicator of patients’ use of
the device [1].
Forty-four patients with cystic ﬁbrosis completed a 13 week handling study in which
they were asked to upload treatment data from home on a weekly basis. Prescription
updates were initiated by the patient or clinician. Data was analyzed and presented
online in graphs so that patients, clinicians and patient support programme personnel
could manage the patients’ treatments. Prescribed use was analyzed using a graph
of 1 week resolution and combined with PLS data to calculate adherence.
Average patient TA for 38 patients over 13 weeks was categorized into 3 groups
of low (<50%), medium (50−79%) and high (80%) [2]. Average TA was high in
11 patients and was medium and low in 21 and 6 patients respectively. Mean week
1/ week 13 TA values for high, medium and low adherence groups were: 89%/88%,
78%/67% and 46%/52%. TA improved or remained unchanged in 45% of patients.
This study shows that this technology can identify those with low or variable TA,
which could direct adherence interventions.
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